Compare EWBC & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EWBC | RVMD |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | 809 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 15.2B |
| IPO Year | 1999 | 2020 |
| Metric | EWBC | RVMD |
|---|---|---|
| Price | $113.58 | $77.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $124.42 | $77.47 |
| AVG Volume (30 Days) | 691.5K | ★ 2.5M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 14.57 | N/A |
| EPS | ★ 9.07 | N/A |
| Revenue | ★ $2,572,339,000.00 | N/A |
| Revenue This Year | $8.44 | N/A |
| Revenue Next Year | $7.04 | $714.50 |
| P/E Ratio | $12.52 | ★ N/A |
| Revenue Growth | ★ 6.63 | N/A |
| 52 Week Low | $68.27 | $29.17 |
| 52 Week High | $117.00 | $81.49 |
| Indicator | EWBC | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 64.72 |
| Support Level | $112.63 | $74.20 |
| Resistance Level | $117.00 | $80.44 |
| Average True Range (ATR) | 2.62 | 2.70 |
| MACD | 0.26 | -0.93 |
| Stochastic Oscillator | 65.73 | 58.03 |
East West Bancorp Inc operates in U.S. and Asia. The Bank provides range of personal and commercial banking services to individuals and businesses. In addition to offering traditional deposit products that include personal and business checking and savings accounts, money market, and time deposits, the Bank also offers foreign exchange, treasury management and wealth management services. The Bank has three operating segments, (1) Consumer and Business Banking, (2) Commercial Banking and (3) Treasury and Other. The company generates the majority of its revenue from the Commercial banking segment.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.